Genmab to Present at Jefferies Investor Conference in November

11/8/2012 3:01 PM EST

Genmab A/S
Investor News

Genmab to Present at Jefferies Investor Conference in November

Media Release

Copenhagen, Denmark; November 8, 2012 – Genmab A/S (OMX: GEN) announced today
its CEO, Jan van de Winkel, Ph.D., will present at the Jefferies 2012 Global
Healthcare Conference in London at 10:40AM local time on November 14, 2012.  A
webcast of the presentation will be available on Genmab’s website at
http://ir.genmab.com/events.cfm. 

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer.  Founded in 1999, the company’s first marketed
antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development.  Genmab’s validated and next generation
antibody technologies are expected to provide a steady stream of future product
candidates.  Partnering of innovative product candidates and technologies is a
key focus of Genmab’s strategy and the company has alliances with top tier
pharmaceutical and biotechnology companies.  For more information visit
www.genmab.com. 

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communication 
T: +45 33 44 77 20; M: +45 25 12 62 60; E:  

This Media Release contains forward looking statements. The words “believe”,
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify
forward looking statements. Actual results or performance may differ materially
from any future results or performance expressed or implied by such statements.
The important factors that could cause our actual results or performance to
differ materially include, among others, risks associated with pre-clinical and
clinical development of products, uncertainties related to the outcome and
conduct of clinical trials including unforeseen safety issues, uncertainties
related to product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Media Release nor to confirm such
statements in relation to actual results, unless required by law. 

Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD20®; DuoBody® and UniBody®
are all trademarks of Genmab A/S. Arzerra® is a trademark of GlaxoSmithKline. 

Media Release no. 06
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark